Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
Satraplatin is an oral platinum analog that was tested (in combination with prednisone) in a multinational, double-blind, randomized, placebo-controlled, Phase III clinical trial in patients with metastatic castrate-refractory prostate cancer (CRPC) who had progressed after one prior chemotherapy regimen.
Filed under: Drugs in development | Tagged: castration-resistant prostate cancer, CRPC, satraplatin | Leave a Comment »
In today’s prostate cancer news: More on the effects of hormone therapy on cognitive function and The application to market satraplatin has been withdraw in Europe
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: cancer, cognitive function, hormone, hormone refractory, prostate, satraplatin, therapy | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site